Carl Hennigan

As the temperature goes up, the humidity goes up, and it seems the humidity has a significant impact on the stabilization of the lipid envelope, which is highly fragile and can break down quite easily if you wash your hands.

And the other factor is UV light seems to be important.

So being outside is actually a good thing in that UV light and a higher temperature should, if it operates like all the other respiratory viruses, actually destabilize the virus, if you like, make it more fragile, and we should see a seasonal dip occur.

There are just some slight concerns because with MERS and SARS in the past, that didn't quite happen in the same way.

Nobody's quite sure about that.

But actually, as we seem to warm up and go above 14 degrees C, which it is today, we should see an impact on the virus and its ability to transmit.

It's not often I am sort of short of words, but I am

feeling incredibly disheartened and disillusioned by what's going on.

It's sort of amplifying all the problems that we've observed for the last 20, 30 years are coming right into a funnel to show 90% of the data going, patients going into trials are wasted.

The trials are done badly.

They're not asking the right questions in the right way.

There's no standardization.

And we're sat here wasting an opportunity to understand what's going on.

I think it's incredibly important we really grasp this message.

I saw a report that came out of a few case series claiming remdesivir worked.

And this was in five patients, of which three of them had remdesivir.

But interestingly, of the two severe cases, they'd already gone beyond their viral load, so it already waned.

And that's one of the crucial problems here.

Most of the disease, the COVID disease, is coming beyond the virus for some patients.

And today I read a report which is saying, the manufacturer is saying, it's more likely to work in milder cases early on in the disease and not later on.